Ethyl 2-ethoxy-3-[4-[(2,2-diethoxy)ethoxy]phenyl]-2-propenoate | 222555-08-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Ethyl 2-ethoxy-3-[4-[(2,2-diethoxy)ethoxy]phenyl]-2-propenoate
• 英文别名: ethyl 3-[4-(2,2-diethoxyethoxy)phenyl]-2-ethoxyprop-2-enoate
• CAS: 222555-08-0
• 化学式: C₁₉H₂₈O₆
• 分子量: 352.428
• InChiKey: SFAPNALOSHJWIM-UHFFFAOYSA-N

物化性质

• 沸点：
  462.3±45.0 °C(predicted)
• 密度：
  1.081±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  25
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  63.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  ethyl(diethylphosphono)ethoxyacetate 、 4-(2,2-二乙氧基乙氧基)苯甲醛 以 四氢呋喃 为溶剂， 以88%的产率得到Ethyl 2-ethoxy-3-[4-[(2,2-diethoxy)ethoxy]phenyl]-2-propenoate
  参考文献：
  名称：

  Benzothiazin and benzoxazin derivatives; their preparation and uses

  摘要：

  本发明涉及新型抗肥胖和降胆固醇化合物，它们的衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。更具体地说，本发明涉及一般式（I）的新型β-芳基-α-氧基取代烷基羧酸，其衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。

  公开号：

  US06130214A1

文献信息

• Heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
  申请人：Dr. Reddy's Laboratories Limited

  公开号：US06664411B2

  公开（公告）日：2003-12-16

  The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereosomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, novel intermediates and pharmaceutical compositions containing them.

  本发明涉及一种新型的抗肥胖和降胆固醇的化合物，它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。更具体地，本发明涉及一种新型的β-芳基-α-氧基取代烷基羧酸的一般式（I），它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。本发明还涉及一种制备上述新化合物、类似物、衍生物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂、新型中间体和含有它们的制药组合物的方法。
• Intermediates of benzoxazinone derivatives and preparation thereof
  申请人：Reddy's Laboratories Ltd.

  公开号：US06331627B1

  公开（公告）日：2001-12-18

  The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereo-somers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, novel intermediates and pharmaceutical compositions containing them.

  本发明涉及一种新型的抗肥胖和降低胆固醇的化合物，它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物。更具体地说，本发明涉及一种新型的β-芳基-α-氧基取代的烷基羧酸，其一般式为(I)，其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物。本发明还涉及一种制备上述新型化合物、类似物、衍生物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂、新型中间体和包含它们的药物组合物的方法。